/
GNLX
$2.90+$0.03 (+1.05%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$128.7M
45M shares
52-week range
$2.29 – $8.54
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.93%
Moderate
Price (6 mo)
Loading chart…
Change$-3.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $11.1M | $170.0K | $8.0K | $8.0K |
| Cost of revenue | $0 | $658.0K | $895.0K | $968.0K | $1.0M | $903.0K | $574.0K |
| Gross profit | $0 | −$658.0K | −$895.0K | $10.1M | −$848.0K | −$895.0K | −$566.0K |
| Gross margin | — | — | — | 91.3% | -498.8% | -11187.5% | -7075.0% |
| R&D | $7.5M | $6.2M | $6.3M | $9.1M | $12.8M | $19.0M | $19.9M |
| Operating income | −$10.9M | −$12.4M | −$14.6M | −$3.0M | −$24.2M | −$31.7M | −$33.2M |
| EBITDA | −$10.5M | −$11.8M | −$13.7M | −$1.7M | −$26.5M | −$29.0M | −$31.6M |
| Net income | −$11.6M | −$14.9M | −$17.8M | −$5.2M | −$28.3M | −$29.9M | −$32.1M |
| Net margin | — | — | — | -47.0% | -16645.3% | -373362.5% | -401812.5% |
| EPS (diluted) | -0.49 | -0.58 | -0.69 | -0.21 | -1.16 | -0.95 | -0.86 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-0.81 | $-0.83–$-0.80 | 4 |
| 2027 | $12M | $-0.76 | $-0.76–$-0.76 | 3 |
| 2028 | $88M | $-0.13 | $-0.99–$0.64 | 4 |
| 2029 | $188M | $0.71 | $0.71–$0.71 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Genelux Corporation Common Stock
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
www.genelux.com- Employees
- 26
- IPO / List date
- Jan 26, 2023
- HQ
- WESTLAKE VILLAGE, CA
Held by traders on TradeandTell
No one on the platform currently holds GNLX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 12,200 | $29.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GNLX yet.
